Bafna Pharmaceuticals Announces Board and Committee Restructuring

Confident Investing Starts Here:

The latest update is out from Bafna Pharmaceuticals Limited ( (IN:BAFNAPH) ).

Bafna Pharmaceuticals Limited announced the retirement of Mr. Palamadai Krishnan Sundaresan as an Independent Director, effective June 24, 2025. This change led to the reconstitution of the Audit and Nomination & Remuneration Committees, ensuring continued compliance with regulatory requirements. The new committee members include Mr. Navin Kumar as Chairman of the Audit Committee and Mrs. Ravichandran Chitra as Chairperson of the Nomination and Remuneration Committee. Despite the changes, the board and its committees remain in compliance with applicable laws, maintaining stability in the company’s governance structure.

More about Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the manufacturing and distribution of pharmaceutical products. The company is based in Chennai, India, and is known for its commitment to quality and compliance with industry regulations.

Average Trading Volume: 1,035

Current Market Cap: 1.75B INR

Learn more about BAFNAPH stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks’

Best Online Brokers

guide, and find the ideal broker for your trades.

Report an Issue

No Byline Policy

Editorial Guidelines

Corrections Policy

Source